LCGC Columnist Anurag Rathore Receives Agilent Thought Leader Award
Professor Anurag Rathore, a scientist at the Indian Institute of Technology (IIT) in Delhi, is the first researcher based in India to receive this award.
Agilent Technologies Inc. has honored Professor Anurag Rathore, a scientist at the Indian Institute of Technology (IIT) Delhi, with the Agilent Thought Leader Award, for his contributions to the field of biopharmaceutical research and his work with advanced methods for molecular characterization of biosimilars.
“I feel humbled to be chosen for an Agilent Thought Leader Award,” said Rathore. “As one of the many researchers at IIT Delhi working in the new COVID-19 normal, this is an encouraging and welcome event. The award will propel me to work harder as we strive to bring the technologies and products we have been working on to market.”
The award Rathore received includes new Agilent instrumentation equipment, including a liquid chromatography–QTOF-mass spectrometry (LC-QTOF-MS) instrument, an automated liquid handling platform, and a two-dimensional LC (2D-LC) system. Rathore also received a grant that will be used to promote academic-based research on critical areas that are impacting the biopharmaceutical industry.
Agilent is invested in developing workflows to streamline the analysis of critical charge and glycosylation heterogeneity of monoclonal antibodies. Rathore’s laboratory is focusing on the best practices toward molecular characterization of monoclonal antibody–based biosimilars. The goal of Rathore’s laboratory work is to create best practices that facilitate commercialization of biotech drugs.
Rathore, in addition to his work at IIT, also serves as a regular columnist for LCGC, where he is the editor of the “Focus on Biopharmaceutical Analysis” column.
The Agilent Thought Leader Award program promotes fundamental scientific advances by contributing financial support, products, and expertise to the research of influential thought leaders in the life sciences, diagnostics, and chemical analysis space. Further information is available on the Agilent Thought Leader Award web page.
AI and GenAI Applications to Help Optimize Purification and Yield of Antibodies From Plasma
October 31st 2024Deriving antibodies from plasma products involves several steps, typically starting from the collection of plasma and ending with the purification of the desired antibodies. These are: plasma collection; plasma pooling; fractionation; antibody purification; concentration and formulation; quality control; and packaging and storage. This process results in a purified antibody product that can be used for therapeutic purposes, diagnostic tests, or research. Each step is critical to ensure the safety, efficacy, and quality of the final product. Applications of AI/GenAI in many of these steps can significantly help in the optimization of purification and yield of the desired antibodies. Some specific use-cases are: selecting and optimizing plasma units for optimized plasma pooling; GenAI solution for enterprise search on internal knowledge portal; analysing and optimizing production batch profitability, inventory, yields; monitoring production batch key performance indicators for outlier identification; monitoring production equipment to predict maintenance events; and reducing quality control laboratory testing turnaround time.
